EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Association between papillary thyroid cancer and XRCC6 gene polymorphisms in the Turkish population

EGEMEN AKGÜN, FADİME MUTLU İÇDUYGU, DEMET ŞENGÜL, EBRU ALP, MEHMET ALKANAT, AYSEGÜL CEBİ, TUNCER OZTURK

Turkish Journal of Medical Sciences · 2024-01-01 · 54 (6) · 1215-1222

DOI: 10.55730/1300-0144.5902 ↗
AstrattDettalji biblijografiċi

Astratt

Background/aim: This study aims to investigate the association between rs2267437, rs5751129 and rs132770 polymorphisms of the XRCC6 gene, which plays a role in repairing DNA double strand breaks, and the risk of Papillary Thyroid Cancer (PTC).Methods: The study included 150 patients who had been diagnosed with PTC and 204 healthy control subjects. Genotyping of SNPs was performed by Polymerase Chain Reaction - Restriction Fragment Length Polymorphism method (PCR - RFLP).Results: In rs2267437 polymorphism, individuals with GG genotype had lower risk of PTC than wild-type CC genotype (p=0.037, 95% CI=0.19-0.96, OR=0.67). The combined genotypes CG+GG were found to be related to a reduced risk of PTC compared to the wild-type CC (p=0.023, 95% CI=0.40-0.94, OR=0.61) in the recessive model (GC+GG vs. CC). In addition, a query of the Genotype-Tissue Expression (GTEx) database showed that the rs2267437 polymorphism may alter the expression level of XRCC6 in whole blood (p=0.0009) but not in thyroid tissue. There were no significant association of rs5751129 and rs132770 polymorphisms with PTC.Conclusion: In conclusion, this study demonstrated that rs2267437 polymorphism may have a protective effect against PTC in the Turkish population. However, rs5751129 and rs132770 polymorphisms were not associated with the disease.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →